Shpa guidelines for medicines prepared in australian hospital pharmacy departments shpa manufacturing working party

Journal of Pharmacy Practice and Research

Volumn 40, Issue 2, 2010, Pages 133-143

  Davis, Mel ^a   Thornton, Penny ^a   Cook, Graham ^a   Andrews, Siobahn ^a   Sluggett, Andrew ^a   Abercrombie, Jackie ^a   Middleton, Megan ^a   Coulthard, Kingsley ^a   Thomson, Bill ^a   Burridge, Nicki ^a  

^a SHPA Manufacturing   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASEPSIS; AUSTRALIA; HAND WASHING; HOSPITAL PHARMACY; HYGIENE; MEDICAL EDUCATION; MEDICAL STAFF; MEDICINE; OCCUPATIONAL SAFETY; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW;

EID: 77954874446     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2010.tb00521.x     Document Type: Review

References (51)

1. National Coordinating Committee on Therapeutic Goods. Standard for the preparation of pharmaceuticals in Australian hospital pharmacy departments. Aust J Hosp Pharm 1994;24:182-8.
2. Pharmaceutical Inspection Co-operation Scheme. PIC/S guide to good practices for the preparation of medicinal products in healthcare establishments. PE 010-3. Geneva: Pharmaceutical Inspection Co-operation Scheme; 2008. Available from .
3. SHPA Committee of Specialty Practice in Oncology. SHPA standards of practice for the safe handling of cytotoxic drugs in pharmacy departments. J Pharm Pract Res 2005;35:44-52.
4. International Society of Oncology Pharmacy Practitioners. Standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007;13(suppl):1-81.
5. Standards Australia/Standards New Zealand. AS/NZS ISO 9000:2006
6. Quality management systems - fundamentals and vocabulary. AS/NZS ISO 9001:2008
7. Quality management systems - requirements. AS/NZS ISO 9004:2000
8. Quality management systems - guidelines for performance improvements. AS/NZS ISO 19011:2003
9. Guidelines for quality and/or environmental management system auditing. Sydney: SAI Global. Available from .
10. Pharmaceutical Society of Australia. Competency standards for pharmacists in Australia. Functional area 5. Canberra: Pharmaceutical Society of Australia; 2003. p. 36-8.
11. Pharmaceutical Society of Australia. The role of non-pharmacist dispensary assistants/technicians. Canberra: Pharmaceutical Society of Australia; 2003.
12. Low J, Macintyre J, McIver L, Lannigan N. The development of a capacity planning model for pharmaceutical services to cancer patients. Pharm J 2003:270; 239-40.
13. Shield K. Capacity planning for chemotherapy. Pharm J 2004:272; 61-2.
14. Australian Government Department of Health and Ageing. Infection control guidelines-for the prevention of transmission of infectious diseases in the health care setting. Canberra: Commonwealth of Australia; 2004.
15. Safe Work Australia. Hazardous substances and dangerous goods. Canberra: Safe Work Australia; 2010. Available from .
16. Worksafe Victoria. Handling cytotoxic drugs in the workplace. Melbourne: Victorian Workcover Authority; 2002.
17. Cleanrooms and associated controlled environments - design, construction and start-up. AS 2567-2002 Laminar flow cytotoxic drug safety cabinets. AS/NZS ISO 14644.1:2002
18. Cleanrooms and associated controlled environments. Sydney: SAI Global. Available from .
19. Pharmaceutical Inspection Co-operation Scheme. PIC/S guide to good manufacturing practice for medicinal products. PE 009-9. Geneva: Pharmaceutical Inspection Co-operation Scheme; 2009. Available from .
20. Standards Australia. AS 1410-2003 Sterilisers - steam - pre-vacuum. AS 2182-1998 Sterilizers - steam - benchtop. AS 2192-2002 Sterilizers - steam - downward-displacement. AS 2487-2002 Dry heat sterilizers. Sydney: SAI Global. Available from .
21. US Pharmacopeial Convention Inc. Chapter <795>. Pharmaceutical compounding - non-sterile preparations. US Pharmacopeia 29-National formulary 24. Rockville: US Pharmacopeial Convention Inc; 2006.
22. Pharmaceutical Society of Australia. Australian pharmaceutical formulary and handbook. 20th ed. Canberra: Pharmaceutical Society of Australia; 2006.
23. US Pharmacopeial Convention Inc. Chapter <797>. Pharmaceutical compounding - sterile preparations. US Pharmacopeia 29-National formulary 24. Rockville: US Pharmacopeial Convention Inc; 2006.
24. European Medicines Agency. ICH Q9 quality risk management. London: European Medicines Agency; 2006. Available from .
25. Therapeutic Goods Administration. Australian regulatory guidelines for prescription medicines. Appendix 14 - stability testing. Canberra: Therapeutic Goods Administration; 2004. Available from .
26. Beaney AM, editor. Quality assurance of aseptic preparation services. 4th ed. London: Pharmaceutical Press; 2006.
27. Didier ME, Fischer S, Maki DG. Total nutrient admixtures appear safer than lipid emulsion alone as regards microbial contamination: growth properties of microbial pathogens at room temperature. J Parenter Enteral Nutr 1998;22:291-6.
28. Flynn EA, Pearson RE, Barker KN. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health Syst Pharm 1997;54:904-12.
29. Food and Drug Administration. Safety alert: hazards of precipitation associated with parenteral nutrition. Am J Hosp Pharm 1994;51:1427-8.
30. Frean JA, Arntzen L, Rosekilly I, Isaacson M. Investigation of contaminated parenteral nutrition fluids associated with an outbreak of Serratia odorifera septicaemia. J Hosp Infect 1994;27:263-73.
31. Solomon SL, Khabbaz RF, Parker RH, Anderson RL, Geraghty MA, Furman RM, et al. An outbreak of Candida parapsilosis bloodstream infections in patients receiving parenteral nutrition. J Infect Dis 1984;149:98-102.
32. Hughes CF, Grant AF, Leckie BD, Baird DK. Cardioplegic solution - a contamination crisis. J Thorac Cardiovasc Surg 1986;91:296-302.
33. Talbot GH, Miller DE, Doorley M, Provencher M, Skros M, Coghlan RJ, et al. Enterobacter cloacae - contaminated cardioplegic solution. Discovery and eradication of a pharmacy reservoir. Am J Infect Control 1984;12:239-44.
34. Hansen EW, Nielsen PL. Intrinsic and extrinsic microbial contamination of home total parenteral nutrition manufactured in eva-infusion bags (the i.v. bag). J Clin Pharm Ther 1987;12:325-31.
35. Anon. Two children die after receiving infected TPN solutions. Pharm J 1994;3(Aug): 2.
36. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anaesthetic, propofol. N Engl J Med 1995;333:147-54.
37. Zacher AN, Zornow MH, Evans G. Drug contamination from opening glass ampules. Anesthesiology 1991;75:893-5.
38. Holmes CJ, Kubey WY, Love DI. Viability of microorganisms in fluorouracil and cisplatin small-volume injections. Am J Hosp Pharm 1988;45:1089-91.
39. Kinnunen U, Koistinen P, Syrjala H, Koskela M. Effects of anti-neoplastic agents on the recovery of bacteria and yeasts in an automated blood culture system. Scand J Infect Dis 2000;32:63-7.
40. Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health Syst Pharm 1998;55:1584-7.
41. Rosner F. Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 1976;37(suppl):1033-6.
42. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos R P. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosphamide in urine of exposed workers. Int Arch Occup Environ Health 1992;64:105-12.
43. Therapeutic Goods Administration. Guidelines for sterility testing of therapeutic goods. Canberra: Therapeutic Goods Administration; 2006. Available from .
44. Gelbart SM, Reinhardt GF, Greenlee HB. Multiplication of nosocomial pathogens in intravenous feeding solutions. Appl Microbiol 1973;26:874-9.
45. Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water for hospitals. Science 1971;173:836-8.
46. Rawal BD, Nahata MC. Variation in microbial survival and growth in intravenous fluids. Chemotherapy 1985;31:318-23.
47. Therapeutic Goods Administration. Minimum incubation period. Canberra: TGA Bulletin; April 1993. Available from .
48. Therapeutic Goods Administration. Therapeutic goods order No. 50. General standard for pyrogen and endotoxin content of therapeutic goods. Canberra: Therapeutic Goods Administration; 1995. Available from .
49. Therapeutic Goods Regulations 1990 (Cth) sch 5A. Available from .
50. Sizer T, Duncombe R, Needle R, Sewell G. Universal operator broth transfer validation. Version 9. London: NHS UK Pharmaceutical Aseptic Services Committee; 2005. Available from .
51. Van Doorne H, Bakker JH, Meevis RF, Marskamp A. Influence of background air on microbial contamination during simulated IV admixture preparation. J Clin Pharm Ther 1994;19:181-7.